liposome-encapsulated daunorubicin-cytarabine
liposome-encapsulated daunorubicin-cytarabine: 13 clinical trials tracked.
liposome-encapsulated daunorubicin-cytarabine evidence translation
What we can confirm
13 tracked trials
What it means
What to watch
Prepared research question
What is verified about liposome-encapsulated daunorubicin-cytarabine, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 2 study sponsors
Clinical Trials (13)showing 10 most recent
Eradicating Measurable Residual Disease in Patients With Acute Myeloid Leukemia (AML) Prior to StEm Cell Transplantation (ERASE): A MyeloMATCH Treatment Trial
Primary endpoint: Frequency of measurable residual disease (MRD) negative complete remission (CR)
A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7+3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who Are Considered High-Risk (Adverse) Acute Myeloid Leukemia As Determined by MYELOMATCH; A MYELOMATCH Clinical Trial
Primary endpoint: Minimal residual disease (MRD) response (Arm 1, 2, 4 and 5)
Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials
Primary endpoint: Timing of treatment Substudy or Tier Advancement Pathway (TAP) assignment
Phase IB/II of CPX-351 as Maintenance Therapy in AML Patients Ineligible for Bone Marrow Transplantation
Primary endpoint: Maximum tolerate dose (Phase 1)
A Prospective, Single Site, Single-Arm Pilot Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms
Primary endpoint: Composite complete remission (CR) rates after one or two courses of CPX-351
A Phase II Study of CPX-351 in Younger Patients < 60 Years Old With Secondary Acute Myeloid Leukemia
Primary endpoint: Complete response rate (morphological complete remission [CR] and incomplete blood count recovery [CRi])
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
Primary endpoint: Event-free survival (EFS)
Randomized Phase 2 Trial of CPX-351 (Vyxeos) vs. CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less-Fit Adults With Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm
Primary endpoint: 3-month Overall Survival (OS)
Phase II Study of the Combination of CPX-351 and Glasdegib in Previously Untreated Patients With Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia
Primary endpoint: Percentage of Participants With Event-Free Survival at 6 Months
Randomized Phase III Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
Primary endpoint: Overall survival (OS) in the restricted set of de novo patients